Clinical trial NCT04007640: Early Screening of Pancreatic Lesions : Development of New Imaging Tools
Official title: Early Stages of Pancreatic Cancer Associated With Obesity and Metabolic Syndrome: Prevention and Screening Tools - Imaging of Fatty Pancreas in Humans: Correlation With Pathological Analysis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pancreatic Cancer
Keywords: Obesity
Diabetes
metabolic syndrome
Magnetic Resonance imaging,
Pancreatic Cancer
preneoplastic lesions
acino-ductal metaplasia,
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
Collaborators: name: National Cancer Institute, France
name: Ligue contre le cancer, France
name: Fondation ARC
First posted: 2019-07-05
Enrollment: 59
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Obesity, diabetes and metabolic syndrome (MS) have all been associated with increase of pancreatic cancer (PK) risk. The precise role of obesity and diabetes and the pathways involved in the early oncogenic phases of PK associated with MS are not well known. The investigators hypothesize that it is possible to decipher this specific "fat-fibrosis-neoplastic sequence", to develop new imaging tools adapted to follow its progression, to test the benefit of treatments to slow this sequence and prevent the development of PK in obese and diabetic patients.This project is in line with a prevention strategy, by planning to understand the physiopathological pathways involved in MS leading to PK, to develop tools useful to screen early precancerous lesions in order to diagnose and treat patients at high risk, before cancer involvement.

This clinical trial is part of the INCA PAIR PANCREAS project : Early stages of pancreatic cancer associated with obesity and metabolic syndrome:

prevention and screening tools - Imaging of fatty pancreas in humans: correlation with pathological analysis, which includes 3 main coordinated objectives an in vitro approach an in vivo approach and this study (clinical approach).

Detailed description: Translational approach with direct application to humans, to test specific imaging MRI sequences in obese patients.

Obesity and metabolic syndrome are a well-known risk factor of pancreatic cancer. Obesity is associated with about 30% increased risk in all studies, but the proportion of obese people varies considerably from one country to another. Therefore, the proportion of cancer attributable to obesity could range from 3% to 16%. Numerous epidemiological studies confirmed that obesity is a risk factor of pancreatic cancer in obese men and women (BMI, kg/m2≥30.0), with a relative risk estimated to 1.76 (95% CI, 0.90-3.45) and 1.70 (95% CI, 1.09-2.64), respectively. As previously demonstrated by partners 9 and 10, obesity is associated with fat pancreatic infiltration and precancerous lesions, such as PanIN lesions in humans. Pancreatic lesions such as adipose infiltration, iron deposits, extent of fibrosis, acino-ductal metaplasia and Pan-IN are involved in pancreatic oncogenesis.

The goal of this study is to be able to diagnose early precancerous states in patients, such as acino-ductal metaplasia (and also PanIN lesions which are more frequently observed in humans,) inflammatory process (iron deposits, fibrosis lesions) and adipose involvement in the context of obesity and metabolic syndrome. Investigators hypothesis is that specific MR imaging sequences, adapted from previous studies in rodents, could be a relevant tool to diagnose early pancreatic lesions and follow their evolution in the context of obesity and metabolic syndrome.

To this aim, the investigators will conduct a study to assess the relevance of MR imaging sequences to diagnose specific pancreatic lesions in obese patients, validated at the microscopic level. The investigators will analyze MR imaging of obese patients (BMI\>30)/non obese patients (BMI\<25) with a planned pancreatic surgery. It will be possible to compare imaging with histology performed on resected parenchyma. The investigators propose a proof-of-concept study aiming at assessing the relevance of specific MR imaging to diagnose early pancreatic lesions in humans and in obese patients especially. MR imaging will be performed in both obese and non obese patients with a planned pancreatic surgery in hospital to resect a benign lesion (such as neuroendocrine tumour or IPMN...). MRI are performed in the normal course of care; their sequences will be adapted for this study. It will be possible to compare imaging with histology of the resected parenchyma.

Eligibility criteria: Inclusion Criteria:

* 1st stage : Volunteers without history of known pancreatic disorders

  - Adults
* 2nd stage : Obese Volunteers

  * Adults with planned hepatic MRI
  * Obese (BMI ≥30)
* 3rd stage : Patients

  * Adults (aged 18-65 years) with a planned pancreatic surgery for benign pancreatic lesions (IPMN, cystic lesions or neuroendocrine tumors)
  * Obese (BMI≥30), overweight (25≤BMI≤29.9) or non-obese patients (18.5\<BMI\<24.9)

Exclusion Criteria:

For volunteers without history of known pancreatic disorders (1st stage):

- Symptoms or past medical history suggesting pancreatic disorders

For all participants (1st, 2nd and 3rd stages) :

* Patients with contraindication to MRI (pacemaker, claustrophobia...)
* Inability to undergo MRI due to weight excess
* Pregnant or breastfeeding woman
* Absence of free and informed consent
* Non affiliation to a social security regime or CMU
* Subject deprived of freedom, subject under a legal protective measure

Primary outcomes:
measure: Quantitative MRI parameters
timeFrame: Day 1
measure: Quantitative MRI parameters
timeFrame: Day 1
measure: Quantitative MRI parameters
timeFrame: Day 1
measure: Quantitative MRI parameters
timeFrame: Day 1
measure: Quantitative MRI parameters
timeFrame: Day 1
measure: fibroinflammatory lesions at histology in obese patients
timeFrame: 2 months
measure: fibroinflammatory lesions at histology in obese patients
timeFrame: 2 months
measure: fibroinflammatory lesions at histology in obese patients
timeFrame: 2 months
Secondary outcomes:
measure: Histologic parameters
timeFrame: 2 months
measure: Histologic parameters
timeFrame: 2 months
measure: Histologic parameters
timeFrame: 2 months
measure: Histologic parameters
timeFrame: 2 months
measure: Histologic parameters
timeFrame: 2 months y
measure: MRI parameters
timeFrame: Day 1
measure: MRI parameters
timeFrame: Day 1
measure: MRI parameters
timeFrame: Day 1I
measure: MRI parameters
timeFrame: Day 1
measure: MRI parameters
timeFrame: Day 1
measure: Biomarkers of pathways activation measured by immunohistochemistry on resected pancreatic parenchyma
timeFrame: 2 months
measure: Biomarkers of pathways activation measured by immunohistochemistry on resected pancreatic parenchyma
timeFrame: 2 months
measure: Biomarkers of pathways activation measured by immunohistochemistry on resected pancreatic parenchyma
timeFrame: 2 months
measure: Biomarkers of pathways activation measured by immunohistochemistry on resected pancreatic parenchyma
timeFrame: 2 months
Other outcomes:
Locations:
city: Clichy
country: France
facility: Hôpital Beaujon
city: Clichy
country: France
facility: Hôpital Beaujon
Study officials:
References: